Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial

Stephanie E Combs, Daniel Habermehl, Meinhard Kieser, Constantin Dreher, Jens Werner, Renate Haselmann, Oliver Jäkel, Dirk Jäger, Markus W Büchler, Jürgen Debus, Stephanie E Combs, Daniel Habermehl, Meinhard Kieser, Constantin Dreher, Jens Werner, Renate Haselmann, Oliver Jäkel, Dirk Jäger, Markus W Büchler, Jürgen Debus

Abstract

Background: Treatment options for patients with locally advanced pancreatic cancer include surgery, chemotherapy as well as radiotherapy. In many cases, surgical resection is not possible, and therefore treatment alternatives have to be performed. Chemoradiation has been established as a convincing treatment alternative for locally advanced pancreatic cancer. Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 1.16 and 2.46 depending on the pancreatic cancer cell line as well as the endpoint analyzed. Japanese Data on the evaluation of carbon ion radiation therapy showed promising results for patients with pancreatic cancer.

Methods and design: The present PHOENIX-01 trial evaluates carbon ion radiotherapy using the active rasterscanning technique in patients with advanced pancreatic cancer in combination with weekly gemcitabine and adjuvant gemcitabine. Primary endpoint is toxicity, secondary endpoints are overall survival, progression-free survival and response.

Discussion: The physical and biological properties of the carbon ion beam promise to improve the therapeutic ratio in patients with pancreatic cancer: Due to the inverted dose profile dose deposition in the entry channel of the beam leads to sparing of normal tissue; the Bragg peak can be directed into the defined target volume, and the sharp dose fall-off thereafter again spares normal tissue behind the target volume. The higher RBE of carbon ions, which has been shown also for pancreatic cancer cell lines in the preclinical setting, is likely to contribute to an increase in local control, and perhaps in OS. Early data from Japanese centers have shown promising results. In conclusion, this is the first trial to evaluate actively delivered carbon ion beams in patients with locally advanced pancreatic cancer within a dose-escalation strategy.

Trial registration: NCT01795274.

Figures

Figure 1
Figure 1
PHOENIX-01-Trial scheme.

References

    1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–1057. doi: 10.1016/S0140-6736(04)15841-8.
    1. Buchler MW, Kleeff J, Friess H. Surgical treatment of pancreatic cancer. J Am Coll Surg. 2007;205:S81–S86.
    1. Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, Yeo CJ. et al.DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol. 1998;67:151–159. doi: 10.1002/(SICI)1096-9098(199803)67:3<151::AID-JSO2>;2-8.
    1. Allison DC, Bose KK, Hruban RH, Piantadosi S, Dooley WC, Boitnott JK. et al.Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy. Ann Surg. 1991;214:648–656. doi: 10.1097/00000658-199112000-00002.
    1. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA. et al.Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–579. doi: 10.1016/S1091-255X(00)80105-5.
    1. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE. et al.A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg. 2006;10:1338–1345. doi: 10.1016/j.gassur.2006.09.008.
    1. Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J. et al.Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705–1710. doi: 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>;2-4.
    1. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW. et al.Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487–3495. doi: 10.1200/JCO.2007.15.8642.
    1. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H. et al.Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–1046. doi: 10.1245/ASO.2006.08.011.
    1. Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS. et al.Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:801–808. doi: 10.1016/j.ijrobp.2006.12.053.
    1. Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, Wautot V. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial. Int J Radiat Oncol Biol Phys. 2010;77:1426–1432. doi: 10.1016/j.ijrobp.2009.06.053.
    1. Shibuya K, Oya N, Fujii T, Doi R, Nakamura A, Matsuo Y. et al.Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am J Clin Oncol. 2011;34(2):115–119.
    1. Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K. et al.Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol. 2001;28:25–33.
    1. Haddock MG, Swaminathan R, Foster NR, Hauge MD, Martenson JA, Camoriano JK. et al.Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol. 2007;25:2567–2572. doi: 10.1200/JCO.2006.10.2111.
    1. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP. et al.Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001;8:123–132. doi: 10.1007/s10434-001-0123-4.
    1. Mornex F, Girard N, Delpero JR, Partensky C. Radiochemotherapy in the management of pancreatic cancer–part I: neoadjuvant treatment. Semin Radiat Oncol. 2005;15:226–234. doi: 10.1016/j.semradonc.2005.04.008.
    1. White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK. et al.Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001;8:758–765. doi: 10.1007/s10434-001-0758-1.
    1. Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F. et al.Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol. 2012;7:28. doi: 10.1186/1748-717X-7-28.
    1. Quiros RM, Brown KM, Hoffman JP. Neoadjuvant therapy in pancreatic cancer. Cancer Invest. 2007;25:267–273. doi: 10.1080/07357900701206356.
    1. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B. et al.Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–1339. doi: 10.1001/archsurg.1992.01420110083017.
    1. Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ. et al.A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14:2088–2096. doi: 10.1245/s10434-007-9384-x.
    1. Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A. et al.Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol. 2006;13:1201–1208. doi: 10.1245/s10434-006-9032-x.
    1. Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J. et al.Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2003;7:766–772. doi: 10.1016/S1091-255X(03)00113-6.
    1. Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW. et al.A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg. 1995;169:71–77. doi: 10.1016/S0002-9610(99)80112-3.
    1. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G. et al.Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5:121–130. doi: 10.1016/S1091-255X(01)80023-8.
    1. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW. et al.Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–3502. doi: 10.1200/JCO.2007.15.8634.
    1. Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C. et al.Randomized phase II–study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer–PARC: study protocol [ISRCTN56652283] BMC Cancer. 2005;5:131. doi: 10.1186/1471-2407-5-131.
    1. Matsui Y, Asano T, Kenmochi T, Iwakawa M, Imai T, Ochiai T. Effects of carbon-ion beams on human pancreatic cancer cell lines that differ in genetic status. Am J Clin Oncol. 2004;27:24–28. doi: 10.1097/.
    1. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953–964. doi: 10.1200/JCO.2006.09.7816.
    1. Yamada S, Shinoto M, Imada H, Yasuda S, Kamada T, Tsujii H. Carbon ion radiotherapy for patients with gastrointestinal cancer. PTCOG 49. Chiba, Japan: Ref Type: Generic; 2010.
    1. Herfarth KK, Debus J, Lohr F, Bahner ML, Fritz P, Hoss A. et al.Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys. 2000;46:329–335. doi: 10.1016/S0360-3016(99)00413-7.
    1. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE. et al.Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101:708–720. doi: 10.1093/jnci/djp079.
    1. Gillen S, Schuster T, Meyer Zum BC, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267. doi: 10.1371/journal.pmed.1000267.
    1. Schulz-Ertner D. The clinical experience with particle therapy in adults. Cancer J. 2009;15:306–311. doi: 10.1097/PPO.0b013e3181b01922.
    1. Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol. 2012;42:670–685. doi: 10.1093/jjco/hys104.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe